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Abstract
Background: Missense mutation of VHL gene is frequently detected in type 2 VHL diseases and linked to a wide
range of pVHL functions and stability. Certain mutant pVHLs retain ability to regulate HIFs but lose their function by
instability. In this case, regulating of degradation of mutant pVHLs, can be postulated as therapeutic method.
Method: The stability and cellular function of missense mutant pVHLs were determine in HEK293T transient
expressing cell and 786-O stable cell line. Ubiquitination assay of mutant VHL proteins was performed in vitro
system. Anticacner effect of adenovirus mediated shUCP expressing was evaluated using ex vivo mouse xenograft
assay.
Results: Three VHL missense mutants (V155A, L158Q, and Q164R) are directly ubiquitinated by E2-EPF UCP (UCP) in
vitro. Mutant pVHLs are more unstable than wild type in cell. Missense mutant pVHLs interact with UCP directly in both
in vitro and cellular systems. Lacking all of lysine residues of pVHL result in resistance to ubiquitination thereby increase
its stability. Missense mutant pVHLs maintained the function of E3 ligase to ubiquitinate HIF-1α in vitro. In cells
expressing mutant pVHLs, Glut-1 and VEGF were relatively upregulated compared to their levels in cells expressing
wild-type. Depletion of UCP restored missense mutant pVHLs levels and inhibited cell growth. Adenovirus-mediated
shUCP RNA delivery inhibited tumor growth in ex vivo mouse xenograft model.
Conclusion: These data suggest that targeting of UCP can be one of therapeutic method in type 2 VHL disease
caused by unstable but functional missense mutant pVHL.
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Background
The von Hippel-Lindau (VHL) disease is caused by mu-
tation of VHL tumor suppressor gene and classified into
two types depend on genotype-phenotype correlation.
The mutation of Type 1 VHL disease is truncation or
exon deletion and type 2 VHL disease have missense
mutation commonly. Type 2 VHL disease shows a high
risk of pheochromocytoma (PCC) and germ line mis-
sense mutations is subdivided into high risk (2B), low
risk (2A), or absence (2C) of Renal cell carcinoma (RCC)
and heamangioblastoma is correlated with function of
pVHL to impair HIF-1α activity [1, 2]. Regarding to
HIFs regulation, type 1 and type 2B VHL disease have
high defect and type 2A relative low defect. In certain
types 2VHL disease, mutations of VHL gene retain their
functionality to regulating HIFs but they exhibit instabil-
ity of mutant VHL protein [3–5]. However the mecha-
nisms control the instability of missense mutant pVHLs
are still under discovered.
Proteasome dependent proteolysis is efficient and
powerful system for regulating half-life of cellular pro-
teins. Ubiquitination is start signal for proteasomal deg-
radation which is consisted by E1, E2 and E3 enzyme.
pVHL is the substrate recognition component of an E3
ubiquitin ligase complex that also contains elongin B,
elongin C, Cul2, and Rbx1 [6–9]. pVHL has two
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functional domains that directly bind to elongin C and
pVHL substrates, respectively and it targets the HIFs for
ubiquitin-mediated degradation [5, 10–13]. Prolyl-
hydroxylated HIFs are recognized by pVHL, which re-
sults in it being polyubiquitinated and, thereby, targeted
for proteasomal degradation [14, 15]. The different do-
mains of pVHL are also important for its stability be-
cause mutant pVHL which are defective in elongin C
binding, are unstable and are rapidly degraded [16].
pVHL also has role in maintaining extracellular matrix
(ECM) thus pVHL-knock out cells like 786-O or RCC4
revealed loss of assembling fibronectin. The function of
pVHL maintaining ECM is not depend on HIFs [17].
Human E2-EPF UCP (UCP) was the first E2 family
member to be cloned from epidermal tissue [18]. Ex-
pression of UCP is five times higher in common human
cancers than in normal tissues [19, 20] Roos et al. has
been reported that UCP implicated in papillary RCC
which is second most common subtype of kidney cancer
[21]. Recombinant UCP is a bifunctional enzyme that is
capable of catalyzing E3-independent and E3-dependent
ligation of ubiquitin and UCP targets pVHL for
ubiquitin-mediated degradation [22, 23]. Since UCP im-
pair to tumorigenesis, we examined whether UCP can
degrade V155A, L158Q and Q164R missense mutant
pVHLs which are linked to RCC. In this study, new bio-
chemical mechanism of instability of missense mutant
pVHL is provided and UCP can be served as a thera-
peutic target for RCC which is related missense muta-
tion of VHL gene.
Methods
Antibodies and reagents
Anti-Flag, anti-GST and anti-b-actin antibodies were
purchased from SIGMA-Aldrich. Anti-HA antibody was
purchased from AbFrontier, and anti-His antibody was
purchased from Millipore. Human anti-HIF-1α was pur-
chased from BD Pharmingen, and human anti-HIF-2α
was purchased from Santa Cruz Biotechnology. The
anti-UCP antibody was generated by protocol, as re-
ported previously [23]. The proteasome inhibitor
MG132 was purchased from Boston Biochem, and cyclo-
heximide was purchased from SIGMA-Aldrich. Luminol
assay kit was purchased from Promega.
Plasmids
Human UCP, elongin C, HIF1a, and UbcH5C cDNA
molecules were supplied by the 21C Frontier Human
Gene-Bank, South Korea. Full-length UCP was cloned
into pET28a (novagen) and pCMV-tag1 (Stratagene).
Wild-type pVHL and point mutants were cloned by
PCR amplification from pFlag-VHL (a gift from S. Cho,
Chung-Ang University, Seoul, South Korea) into
pCDNA3.1+ (Invitrogen), pEBG, pGEX-4 T1 and pET-
28a. The shUCP (5′-AATGGCGATCTGCGTCAAC-3′)
sequence was inserted into the pSUPER vector according
to the manufacturer’s instructions (Invitrogen). The se-
quences of all plasmids were verified by direct sequen-
cing before use. pTK-Hyg (Clontech) was used for
producing HeLa -shUCP expressing constitutive cell
line. Five repeat copies HRE derived from VEGF pro-
moter cloned to pGL3 (Promega).
Cell culture and counting
786-O cells, HEK293T cells and HeLa cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
with 10 % fetal bovine serum (FBS, GIBCO) in a humidi-
fied incubator with 5 % CO2 at 37 °C. The 786–O cell
lines stably expressing exogenous pVHL were trans-
fected with the indicated plasmids or empty vector
(pCDNA3.1), and were cultured with 1 mg/mL geniticin
(G418, GIBCO) for 1 month for single colony selection.
For the cell proliferation assay, the cells were plated at
5 × 103 cells/well in conditioned media on 24-well plates.
At 24 h after seeding, the cells were trypsinized and
counted by a hemocytometer. The viability of cells were
observed by crystal violet staining (0.1 % w/v). Luminol
assay for HRE-luc was performed as manufacturer’s
indication.
Protein stability analysis
The 786-O cell lines stably expressing exogenous HA-
tagged wild-type or mutant pVHLs were treated with
50 μg/ml cycloheximide for 0, 2, 4 and 6 h. At the indi-
cated time points, the cells were harvested, and proteins
were detected by western blot analysis with a VHL anti-
body (BD Pharmiongen). The signal intensity was deter-
mined using densitometer software.
Immunoblot analysis and pull down assay
Cells were lysed on ice using RIPA buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1 % NP40,
0.1 % SDS, 1 mM PMSF, 1X protease inhibitor) and were
separated by 12 % SDS-PAGE. The proteins were trans-
ferred from the gel onto a PVDF membrane (polyvinyli-
dene fluoride, Millipore), and the membrane was
incubated with specific primary antibodies in PBS/0.1 %
Tween20 (PBST) for 2 h at RT or overnight at 4 °C. Sub-
sequently, the membrane was incubated with secondary
antibody in PBST containing 0.5 % skim milk for 1 h at
RT, and the proteins were visualized using a chemilu-
minescence kit (Intron). The cell lysate was prepared in
NET gel buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.1 % NP-40, 1 mM EDTA, pH 8.0) supplemented
complete proteinase inhibitor cocktail (Roche), and
GST-tagged and His-tagged proteins were pulled-down
with the glutathione sepharose beads (GE healthcare)
and Ni-NTA agarose (Qiagen). Proteins were separated
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by SDS-PAGE and detected by immunoblot with anti-
body as indicated.
Purification of recombinant fusion proteins
GST fusion proteins were expressed and purified as de-
scribed by the manufacturer (Amersham). pGEX-4 T1
vector-based GST fusion proteins were induced with
1 mM IPTG for 2 h at 37 °C. Cells were washed with
PBS, resuspended in lysis buffer (PBS, protease inhibiter
cocktail, 1 mM PMSF), and then sonicated on ice. Sol-
uble protein extracts were added to glutathione sephar-
ose 4B resin (Amersham) and incubated for 2 h at 4 °C.
The columns were washed five times with PBS. Bead-
bound proteins were eluted with elution buffer (50 mM
Tris, pH 8.8, 1 mM EDTA, 20 mM glutathione reduced
(GSH), 1 mM PMSF). His-fusion proteins were
expressed and purified as described by the manufacturer
(QIAGEN). pET28a vector-base His fusion proteins were
induced with 1 mM IPTG for 2 h at 37 °C. The cells
were resuspended in lysis buffer (0.5 M NaCl, 5 mM
imidazole, 20 mM Tris, pH 7.9) and then sonicated on
ice. The cell extracts were added to Ni-NTA resin
(QIAGEN) and were incubated for 2 h at 4 °C. The col-
umns were washed five times with wash buffer (0.5 M
NaCl, 60 mM imidazole, 20 mM Tris, pH 7.9). Bead-
bound proteins were eluted with elution buffer (0.25 M
NaCl, 0.5 M imidazole, 10 mM Tris, pH 7.9). After
dialysis, the purified proteins were stored at -70 °C.
Ubiquitination assay
In vivo ubiquitination assay was performed by protocol,
as previously described [23]. For the self-ubiquitination
of UCP, the reaction mixture (50 μl) contained 0.3 μg of
GST-UCP, 0.5 μg of His-E1 and 25 μg/ml Flag-ubiquitin
in reaction buffer (25 mM Tris-Cl, pH 7.5, 1 mM ATP,
5 mm creatine phosphate, 0.5 μg/ml creatine phosphate
kinase, 1 mM DTT, 5 mM MgCl2, 0.5 μg/ml ubiquitin
aldehyde) was used. The mixture was incubated for 1 h
at 37 °C, and then a western blot analysis was performed
using the indicated antibodies. For the ubiquitination of
pVHL by UCP, the reaction mixture (50 μl) containing
0.3 μg of GST-UCP, 0.5 μg of His-E1, 3 μg of His-VHL,
and 25 μg/ml Flag-ubiquitin in reaction buffer was used.
After incubation at 37 °C for 1 h, GST-VHL was pulled
down with glutathione sepharose 4B resin and was ana-
lyzed by SDS–PAGE. For the ubiquitination of HIF-
ODD by the VHL-elongin B-elongin C (VCB) complex,
the 786-O cells were washed and collected in PBS. The
cells were disrupted, using a sonicator, in lysis buffer
(50 mM Tris-HCl, pH7.5, 150 mM NaCl, 0.5 mM
EDTA, 0.1 % NP40, 1 mM PMSF, 1X protease inhibitor).
The cell lysates were centrifuged at 13000 rpm for 1 h at
4 °C. The total reaction volume was 50 μl and contained
50 μg of 786-O cell extracts, 3 μg of GST-ODD, 0.3 μg
of His-VHL, 0.3 μg of UBCH5C, and 0.5 μg of His-E1 in
reaction buffer. The mixtures were incubated for 2 h at
30 °C. After incubation, the reaction mixtures were
pulled down with glutathione sepharose 4B resin and an-
alyzed by SDS–PAGE.
RT-PCR and real time PCR
Total RNA was extracted from cells using an easy-spin
RNA extraction kit (Intron). Complementary DNA
(cDNA) was synthesized using 3–5 μg of total RNA, re-
verse transcriptase (TakaRa, Japan) and oligo (dT) pri-
mer. cDNA was amplified by polymerase chain reaction
using primers specific for each gene (Additional file 5:
Table S1). For the LightCycler (Roche Diagnostics) reac-
tion, LightCycler mastermix and cDNA as the PCR tem-
plate were filled in PCR tube. The mixtures were
centrifuged and placed into the LightCycler rotor. The
following LightCycler experimental run protocol was
used: denaturation (95 °C for 10 min), amplification and
quantification repeated 35 times (95 °C for 15 s, 60 °C
for 10 s, and 72 °C for 60 s) with a single fluorescence
measurement.
Animals and ex vivo xenograft assay
Seven-week-old female BALB/c nude mice were pur-
chased from SLC japan and maintained in a accordance
with guidelines and approval of Institutional Review
Committees for Animal Care and Use, Korea Research
Institute of Bioscience and Biotechnology (KRIBB-AEC-
14024). 786-O and 786-VHL (WT and V155A) cells
were transduced with adenoviral vectors (Ad.shUCP
and Ad.shCont) at 200 MOI for 24 h. And then cells
(107) are transplanted by subcutaneous injection into
nude mice (Japan SLC, Inc.). Tumor size was mea-
sured for 44 days by following procedure, as reported
previously [23, 24].
Statistics
Statistical analysis was carried out using the unipolar,
paired Student t test and the two-sided chi-square test.
Data were considered statistically significant when the P
value was less than 0.05.
Results
Protein instability of missense mutant pVHL is caused by
proteasome dependent degradation
To examine missense mutations of VHL gene associated
with type 2 VHL disease, we selected total 7 VHL mis-
sense mutants which were characterized as tumorigenic
cluster. Missense mutation like V155A, L158Q, Q164R,
R167Q and L188V were located on α-domain which
interacted to Elongin C. Mutants such as N78S and
Y112H were involved in role for recognition of HIF-1 α
protein (Additional file 1: Figure S1A). UCP was found
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to ubiquitinate all of them in vitro ubiquitination assay
using recombinant missense mutant pVHL (Additional
file 1: Figure S1B).
We examined whether UCP regulated the stability of
the selected three missense mutant pVHLs. HEK293T
cells were transfected with the Flag-UCP plasmid and
each mutant VHL plasmid respectively, either in the
presence or absence of MG132, a proteasome inhibitor
(Fig. 1a). Missense mutant pVHLs were degraded by
UCP, but this was inhibited by MG132. Then, we con-
firmed the changing half-life of the mutant pVHLs using
cycloheximide (CHX)-mediated pulse chase assay in
both HEK293T (Fig. 1b) and 786-O cells (Fig. 1c). The
three mutant pVHLs had shorter half-life than the wild
type pVHL in both cell lines (Fig. 1d and e). A relatively
higher transfection efficiency was observed for
HEK293T cells than for 786-O cells, and this led to an
increased half-life of mutant pVHLs in HEK293T cells as
compared to 786-O cells (Fig. 1b and c). Furthermore,
the L158Q mutant was so unstable in 786-O cells that it
was nearly undetectable (Fig. 1c). We examined that the
protein levels of the mutant pVHLs were dependent on
the UCP levels in the cells. We co-transfected the VHL
missense mutants with the shUCP plasmid into
HEK293T cells and confirmed that UCP depletion in-
creased the levels of the missense mutant pVHL (Fig. 1f ).
These result led us to conclude that UCP regulates the
stability of missense mutant pVHL.
Fig. 1 UCP degraded missense mutant pVHLs (V155A, L158Q and Q164R) via proteasome pathway and decrease half-life in cell. a HEK293T cells
were transfected with HA-tagged mutant VHL (V155A, L158Q, Q164R) and/or Flag-UCP and cells were incubated for 16 h either in the presence
or absence of 10 uM MG132 at 36 h post- transfection. b Mutants VHL were transfected into 293 T cell. At 36 h post- transfection. Cells were
treated with cyclohexamide (CHX) for 0, 2, 4, 6 h then and immunoblotted as indicated. c 786-O cell lines constitutively expressing mutant pVHL
were treated with cyclohexamide (CHX) for 0, 2, 4, 6 h then and immunoblotted as indicated. Calculation of protein degradation kinetic of both
HEK293T (d) and 786-O (e) cell lines was revealed that mutant pVHLs have shortened half-life (n = 3, p < 0.01). f HEK293T cells were transfected
with HA-tagged mutant VHL and/or UCP-shRNA and then at 48 h post- transfection, cell were harvested and immunoblotted as indicated
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Missense mutations of VHL gene associated with RCC
were targeted by UCP directly in vitro and in vivo
Recombinant proteins of three missense mutants (V155A,
L158Q and Q164R) were purified and provided to UCP as
substrates for polyubiquitination assay. UCP bound and
ubiquitinated all mutant pVHLs (Fig. 2a and b). In the
ubiquitination assay, UCP generated ubiquitin chains on
the mutant pVHLs more easily than on wild-type pVHL.
UCP also recognized mutant pVHLs and ubiquitinated
them in a cellular system (Fig. 2c and d). Interestingly, the
L158Q mutant was the most highly ubiquitinated mutant
in the cellular system. GST-tagged pVHL mutants were
co-transfected into HEK293T cells with a HA-tagged
ubiquitin plasmid, and then, the cells were exposed to the
proteasome inhibitor MG132 for 12 h. The ubiquitinated
mutant pVHLs were pulled down by GST resin and de-
tected by anti-HA antibodies. The results of both in vitro
and in cellular assays suggested that missense mutations
in VHL gene do not alter the protein folding structure
that is necessary for its interaction with UCP.
Altering pVHL lysine residues increases the life span in a
cellular system
Ubiquitin chain elongation formed at the lysine residue
of the substrate with certain linkage. The protein of
VHL has three lysine residues (K159, K171 and K196),
Fig. 2 UCP interacted missense mutant pVHLs directly and ubiquitinated in vitro and in cell. a GST tagged recombinant proteins of mutant
pVHLs were ubiquitinated by UCP in vitro. GST-pVHL (V155A, L158Q, Q164R) and/or His-UCP protein were incubated at 37 °C in the presence of
E1 and Flag-ubiquitin. GST-pVHL polyubiquitination was detected by western blot with Flag antibody. b Each mutant GST-VHL protein and
His-UCP protein were mixed and then detected the interaction using GST-pull down assay. Bound UCP protein was detected by immunoblot.
c Plasmid expressing GST tagged mutant VHL were transfected into HEK293T in the presence of MG132 for 16 h and then ubiquitinated forms
were isolated using GST resin and then detected by immunoblot using antibody to detect HA-Ub conjugated pVHL. d Plasmid expressing GST
tagged mutant VHL and /or Flag-UCP were transfected into HEK293T in the presence of MG132 for 16 h and then mixed and then detected the
interaction using GST-pull down assay. Bound UCP protein was detected by immunoblot
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therefore we hypothesized that the polymerization of
ubiquitin by UCP occurred at the lysine residues of
pVHL (Fig. 3a). We examined the stability of pVHL mu-
tants with alanine substitutions at 1 or more of pVHL’s
lysine residues. A mutant with a double alanine substitu-
tion for lysine (K159, K171 and K196) and a lysine zero
mutant (deletion of all lysine residues) were constructed
into a mammalian expression vector to examine their
degradation in a cellular system. HA-tagged lysine mu-
tant VHL plasmids and a Flag-tagged UCP plasmid were
co-transfected into HEK293T cells and then protein
levels were analyzed by a western blot assay (Fig. 3b).
Since UCP ubiquitinated both pVHL and single lysine mu-
tant but not lysine zero mutant pVHL (Additional file 3:
Figure S3), the lysine zero mutant was resistant to the deg-
radation by UCP (Fig. 3b). The levels of lysine altering mu-
tant pVHLs were determined using a CHX-mediated assay,
and the lysine zero mutant was more stable than the single
lysine mutant in both HEK293T and 786-O cells (Fig. 3c
and d). pVHL lysine zero mutant showed the longest half-
life and pVHL K159 mutant showed relatively longer half-
life than the other mutants (Fig. 3e and f). These data
suggested that UCP formed polyubiquitin chain on lysine
residue of pVHL such as other E3 ubiquitin ligase, thereby
Fig. 3 Lysine deficient mutant pVHL were resistant to degradation therefore increased half-life. a Schematic diagrams for various lysine deficient VHL
mutants used in this study. b HA tagged lysine deficient mutant VHL were transfected into HEK293T and/or Flag-UCP. At 48 h post-transfection, cells
were harvested and analyzed by western blotting. c Each lysine mutated pVHL expressing plasmids were transfected in HEK293T. At 36 h
post- transfection. Cells were treated with cyclohexamide (CHX) for 0, 2, 4, 6 h then and immunoblotted as indicated. d 786-O cell lines
constitutively expressing lysine mutant (K159, K171, K196, Lysine zero) stable cell lines were treated with cyclohexamide (CHX) for 0, 2, 4,
6 h then and immunoblotted as indicated. Calculation of protein degradation kinetics of HEK293T (E) and 786-O (f) cell lines showed that
half-life of lysine deficient pVHL were increased (n = 3, p < 0.01)
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altering lysine residue of pVHL can be a way to evade
degradation.
Missense mutant pVHLs form the VBC complex and retain
E3 ubiquitin ligase activity
To examine the ability of missense mutant pVHLs to form
the E3 ligase complex and recognize HIFs, we performed
a GST-pull down assay. GST-tagged elongin C was trans-
fected with 3 missense mutant pVHLs (V155A, L158Q
and Q164R) into HEK293T cells. Because the mutated
amino acids are located near the pVHL site which is
known as the elongin C binding site, we hypothesized that
these mutants would not be capable of binding elongin C.
However, all of missense mutant pVHLs bound to elongin
C (Fig. 4a). The L158Q missense mutant pVHL exhibited
the weakest interaction affinity as compared to the affinity
of wild-type pVHL. Next, we transfected GST-tagged
VHL missense mutant plasmids with or without the Flag-
tagged HIF-1 α expression vector into HEK293T cells and
performed a GST-pull down assay to detect HIF-1α. Three
of missense mutant pVHLs recognized HIF-1 α with the
same affinity (Fig. 4b). All of missense mutant pVHLs ex-
cept V158Q used in this study, can build VBC complex in
overexpressing system (Additional file 2: Figure S2).
Fig. 4 Missense mutant pVHL constitute E3 ubiquitin complex and retain functionality. a HEK293T cells were transfected with plasmid expressing
HA tagged mutant VHL and/or GST tagged Elongin C. At 48 h post-transfection, cells were harvested and lysed in NET gel buffer and then
detected the interaction using GST-pull down assay. Interacted mutant pVHLs were detected by immunoblot as indicated. b HEK293T cells were
transfected with plasmid expressing GST tagged mutant VHL and/or Flag tagged HIF-1α. At 48 h post-transfection, cells were harvested and lysed
in NET gel buffer and then detected the interaction using GST-pull down assay. c HEK293T cells were transfected with HA-tagged mutant VHL
and/or Flag-HIF. Cells were incubated for 16 h either in the presence or absence of 10 uM MG132 at 36 h post- transfection. Protein levels are
detected by immunoblotting as indicated. d Calculation of levels of HIF-1α at figure C and showed mutant pVHL degraded HIF-1α in cells.
e Recombinant missense mutant pVHLs and GST-ODD protein were purified for in vitro ubiquitination assay. Cell lysates from 786-O cell line were
provided as supplier of VBC components. His-tagged VHL proteins were incubated with E1, Flag-ubiquitin and GST-ODD protein with cell lystate
at 37 °C for 1 h. GST-ODD protein was pulled-down with glutathione sepharose beads and ubiquitinated forms were detected by immunoblot
with Flag antibody
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Active pVHL ubiquitinated HIFs and the polyubi-
quitination of HIFs led to proteasome-dependent deg-
radation of HIFs by cell-induced proteasome-mediated
proteolysis. As expected, pVHL missense mutants in-
duced the proteasome-dependent proteolysis of HIF-
1α, and this proteolysis was inhibited by MG132
(Fig. 4c and d). The functionalities of pVHL missense
mutants were tested by an in vitro ubiquitination
assay with the ODD domain of HIF. pVHL missense
mutants formed the VBC complex and directly ubi-
quitinated HIF-1α in vitro (Fig. 4e).
The pVHL missense mutants modulate the cellular
function of HIFs
To examine whether missense mutant pVHLs modulate
HIFs target genes, each missense mutant VHL gene was
transfected into 786-O renal carcinoma cells, and then,
HIF-2α and its targets were analyzed at the protein and
mRNA levels. Missense mutant pVHL decreased the
protein levels of HIF-2α and cyclin D1 (Fig. 5a) and the
mRNA levels of Glut1 and VEGF were also decreased,
as determined by real time PCR and conventional RT-
PCR assays (Additional file 4: Figure S4). These events
Fig. 5 HIF-2α and its target genes was regulated by functional mutant pVHL. a HA tagged wild type and mutant VHL (V155A, L158Q, Q164R)
were transfected into 786-O cells. At 48 h post-transfection, cells were lysed in RIPA buffer and then the proteins which are related in UCP-VHL-
HIF pathway and cyclin D1 were detected by immunoblot as indicated. b HeLa expressing shVHL was transfected with HRE-Luc plasmid and/or
missense mutant pVHL expressing plasmid. At 48 h post-transfection, cells were lysed in luminol assay buffer. Functionality of missense mutant
pVHL was revealed by luciferase activity. mRNA was purified from missense mutant VHL expressing 786-O stable cell line at 48 h after seeding
and it was used for quantitation of transcripts of Glut-1(c) (n = 3, p < 0.01) and VEGF (d) (n = 3, p < 0.05) using LightCycler. e Cell proliferative
changes of each mutant pVHL expressing 786-O stable cell lines were observed by following 1, 2, 3 days using hemocytometric counting method.
f The number and the conditions of cell at final days was observed by hemocytometric counting (n = 3, p < 0.05) and crystal violet staining
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were dependent on the pVHL level; therefore, we con-
cluded that missense mutant pVHLs regulated HIFs and
its targets. The functionalities of missense mutant
pVHLs were tested using a reporter assay with HRE-
luciferase (Fig. 5b). We produced a HeLa cell line ex-
pressing shVHL, which depleted wild-type VHL using
siRNA, and then, each mutant pVHL and pHRE-Luc
was co-transfected into the cell line. Missense mutant
pVHLs downregulated the promoter activity of HRE as
well as the mRNA levels of Glut1 (Fig. 5c) and VEGF
(Fig. 5d); however, L158Q showed little effect on the
HRE promoter because it was expressed at a low level.
These effects of the VHL mutation resulted in a decrease
of the growth rate in the mutant-expressing 786-O cell
lines. Wild-type pVHL showed the greatest reduction in
growth rate, and L158Q did not affect cell growth
(Fig. 5e–f ). The same number of pVHL null 786-O cells
and 786-O cells expressing missense mutant pVHL were
seeded, and their cell numbers were counted every day
for 3 days (Fig. 5e). The cell number at final day after
seeding was counted and stained by crystal violet
(Fig. 5f ). We concluded that missense mutant pVHL
(V155A, L158Q and Q164R) retain activity to regulate
HIFs and the functionality was dependent on expression
level of missense mutant pVHL.
Depletion of UCP suppressed cell growth of the pVHL
mutants in vitro and in vivo
We tested whether UCP depletion could rescue VHL
disease. First, we examined whether the growth rates of
the cell lines expressing mutants pVHL were regulated
by UCP. The 786-O cell lines expressing mutant pVHL
were transduced by an adenovirus containing UCP-
shRNA (Ad.shUCP) with 200 MOI. Cell growth was an-
alyzed by the counting method, and protein levels were
detected by the appropriate antibodies. Ad.shUCP sup-
pressed cell growth in the cell lines expressing mutant
pVHL, especially in the V155A missense mutant pVHL
expressing 786-O cell line but not in the VHL null cell
line (Fig. 6a). Ad.shUCP suppressed UCP expression and
increased the level of pVHL, thereby decreasing the level
of HIF-2α (Fig. 6b). An in vivo assay was conducted
using a mouse xenograft model. The V155A missense
mutant-expressing pVHL 786-O cell line and a VHL
wild-type 786-O cell line were transduced with
Ad.shUCP 200 MOI for 24 h and then transplanted on
Fig. 6 Gain of function for missense mutant pVHL using adenovirus mediated depletion of UCP. a V155A missense mutant pVHL expressing 786-
O stable cell lines were transduced with adenovirus expressing siUCP or siControl at a MOI of 200 and incubated for 48 h. Cells were counted by
hematocytometer (n = 3, p < 0.01) (b) At same time cells were harvested and lysed for analysis of UCP-VHL-HIF pathway. Proteins were monitored
by immunoblot as indicated. c Cells as indicated were transduced adenovirus expressing UCP-siRNA and/or Cont-siRNA at 200 MOI and then
injected into nude mouse subcutaneously (n = 4, p < 0.01). Tumor mass was monitored by 3-4 days during indicated times. d At the end of tumor
size measurement, tumors were excised for immunoblot. Pooled tumor pieces of each group were lysed in tissue lysis buffer and immunoblot
assay was performed as indicated
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the skin of nude mice. Tumor growth was monitored for
44 days. On the last day of tumor measurement, the tu-
mors were excised and then analyzed by western blot-
ting. The inhibition of UCP result in decreasing the
growth of tumors harboring the V155A missense mutant
pVHL and the growth of tumors expressing wild-type
VHL (Fig. 6c and d).
Discussion
pVHL pocess E3 ubiquitin ligase activity to degrade HIFs
which is related in tumor pomoting events but the mecha-
nisms inducing instability of pVHL itself are not clarified
clearly. Based on complex of VCB complex, folding and
conformational chagnes of protein result in proteoso-
mal degradation dependent on chaperones [16, 25]. A
recent findings supported that missense mutant pVHL
was easily degraded, and therefore had shortened
half-life in cell [26, 27]. Missense mutation of VHL
gene is most frequent in type 2 VHL disease. Depend
on ability to control HIFs, it is classified into 2A, 2B
and 2C. In case of type 2C, mutant pVHL retains
function as E3 ubiquitin ligase to HIFs which induce
angiogenic factors and stimulate glucose metabolism
in cancer cells. These information suggest that inhib-
ition or retardation of degrading pVHL is crucial for
gain of function of missense mutant pVHL.
Based on the correlation between functional loss of
pVHL and missense mutations in the VHL disease-
associated tumors, VHL disease was classified into three
clusters [24]. First cluster is formed by the surface resi-
dues are responsible for the interactions between elongin
C and pVHL [10, 13]. The residues V155, L158, Q164
and R167 are the most frequently mutated residues in
VHL syndrome [28]. The residue V155, L163 and V166
are associated in RCC [29]. The second cluster of muta-
tions are located in HIFs protein binding site of pVHL
binding [30]. Tyrosine 98 residue most popular mutated
amino acid in this cluster that involved in tumorigenesis
[31–33]. Last cluster of mutations are located on the β-
domain and residues R79, S80, R82, L89, D121, Q132,
L135, F136, and P138 are reported [34]. We character-
ized 7 VHL missense mutants as Y112H, R167Q, 188 V,
V155A, L158Q, Q164R and N78S. Except V155A, 6 mis-
sense mutant pVHLs were discovered at nature and they
are related with VHL disease [35–39].
UCP has been revealed as a factor that reconganize
and targeted wild type pVHL for proteosomal degrad-
ation thereby stabilize HIFs. Depletion of UCP inhibit
tumor growth and metastasis in vitro and in vivo and it
is highly expressed in various cancer [23]. These findings
lead us examine that UCP could recognize missense mu-
tant pVHL and degrade it proteasome dependently like
wild type pVHL and depletion of UCP level can rescue
function of missense mutant pVHL. UCP was found to
ubiquitinate all of missense mutant pVHL in vitro
(Additional file 1: Figure S1) ubiquitination assay and
these mutant pVHL interacted to HIF-1α (Additional file 2:
Figure S2). These result suggested that tested mutant pVHL
can regulate HIFs activity as far as it is stable. Taken to-
gether, UCP can be a critical factor for regulating HIFs via
targeting missense mutant pVHL in RCC. In order to sug-
gest meaning of UCP-VHL-HIFs axis, we characterized
V155A, L158Q and Q164R missense mutant pVHLs which
are most frequent in RCC. These three missense mutanta-
tions are located near the elongin C binding site of pVHL,
which forms the pVHL-elongin complex to prevent the
degradation of pVHL. UCP also recognized mutant pVHLs
(V155A, L158Q and Q164R) and ubiquitinated them in
vitro and in a cellular system. These missense mutations in
VHL gene do not cause structural changes to the UCP
binding site. Thereby UCP ubiquitinated missense mutant
pVHLs, it caused degradation by proteasomes in cell. Ubi-
quitination by UCP can be a critical factor to determine sta-
bility of missense mutant pVHLs (Figs. 1 and 2). In
addition to ubiquitination, some post translational modifi-
cations of protein by ubiquitn-like molecules like SUMOy-
lation or NEDDylation has been reported as strategy for
regulating protein dynamics in cells. What are major factors
for regulating stability of missense mutant pVHL is still
under question.
The polymerization of ubiquitin occurred at between
glycine of the ubiquitin and the lysine residues of target
protein. Ployubiquitin chain which is attached on lysine,
recognized by 26S proteasome. UCP possess E3 ubiqui-
tin ligase activity to wild type pVHL and VHL protein
has three lysine residues (K159, K171 and K196). We hy-
pothesized that UCP recognize three lysine of pVHL for
ubiquitination. As expectation, pVHL lysine zero mutant
had longest half-life and K159 mutant pVHL was relative
long half-life than the others (Fig. 3). Indeed UCP mostly
did not ubiquitinated lysine zero mutant pVHL in cell
(Additional file 3: Figure S3). But there is significant dif-
ference of ubiquitination between single lysine mutant
(Additional file 3: Figure S3). Therefore, K159 mutant
pVHL is regulated by another mechanism in addition to
ubiquitination. These results suggest that the inhibition
of UCP mediated poly-ubiquitin chain elongation at the
lysine residues of pVHL increased the stability of pVHL
in a cellular system. However, we did not determine
whether these lysine mutants had the same functions as
wild-type pVHL.
The effect of missense mutations in VHL gene was ex-
amined by impairing E3 ligase activity. The E3 ubiquitin
ligase complex, named as the VBC complex, is com-
posed of elongin C, elongin B, Rbx1, cul2 and pVHL,
and it functions as a substrate recognition molecule
[16]. Missense mutant pVHLs formed the VBC complex
and directly ubiquitinated HIF-1 α in vitro even it is
Park et al. BMC Cancer  (2015) 15:800 Page 10 of 13
existed at RCC which is nearby Elongin binding site
(Fig. 4). In fact, L158Q had very weaken interacting af-
finity with Elongin C. These data are collected from over
expression system which might be different from en-
dogenous expression level. Thus, the examined missense
mutations did not impair the E3 ligase activity of pVHL.
Instability is crucial for impairing the functionality of
missense mutant pVHLs. Three missense mutants
(V155A, L158Q, and Q164R) sustained E3 ligase activity
as indicated by their ability for the VBC complex and de-
grade HIF-2 α thereby decreased the expression VEGF,
Glut-1 and Epo, which are target genes of HIF-2α [40]
which promotes tumor cell growth, invasion and regu-
lates glucose metabolism [41]. Protein levels of missense
mutant pVHLs were inversely correlated with HIF-2α
and its functionality to cell growth (Fig. 5). Collectively
in case of three missense mutations of VHL gene
(V155A, L158Q, and Q164R), they had function of
tumor suppressor if they were protected from degrad-
ation. With regards to VHL disease, missense mutation
of VHL gene induced pVHL instability, and the loss of
function of pVHL caused an increase in the cellular level
of HIFs, which promoted cell growth. Thus, we tested
whether UCP depletion could rescue VHL disease par-
ticularly in RCC (Fig. 6). Depletion of UCP increased
protein level of mutant pVHL and inhibited cell growth
in vitro. Since depletion of UCP showed relative higher
inhibition the growth of cell expressing V155A mutant
pVHL than the others, we used cell expressing V155A
mutant pVHL for ex vivo experiment. The UCP level
was decreased and the pVHL level was increased in the
tumor tissues and pVHL induced the expression of fi-
bronectin and E-cadherin but HIF-2α was decreased in
tumor nodules. Tumor microenvironments were com-
posed with heterogeneous cells and molecules [42].
pVHL enhanced extracellular matrix protein, thus pro-
longed the tissue morphology and inhibited tumor
metastasis HIFs independently [17]. V155A pVHL
missense mutant is not existed in nature yet. Thus
these data give biological prospect of new missense
mutation of VHL gene.
Consequently, UCP ubiquitinated missense mutant
pVHLs (V155A, L158Q and Q164R) via proteasomal
degradation. Therefore depletion of UCP can be the
therapeutic method for type 2 VHL disease such as
RCC.
Conclusion
UCP polyubiquitinates and degrades missense mutant
VHL protein in vitro and in cellular system. Thereby
delpletion of UCP restored protein level of V115A,
L158Q and Q164R missense mutant pVHLs and lacking
all of lysine residues of pVHL provided greater stability.
Missense mutant pVHLs ubiquitinated ODD domain of
HIF-1α in vitro. These mutant pVHL regulated target
genes of HIF-2α thereby inhibited cell growth in 786-O
cells depend on expression levels of them. Adenovirus-
mediated shUCP delivery restored missense mutant
pVHLs in vitro. It inhibited cell growth in vitro and
inhibited tumor growth in a 786-V155A-expressing cell
in ex vivo xenograft model. These data suggest that tar-
geting of UCP can be one of therapeutic method in
type 2 VHL disease caused by instability of pVHL
missense mutants.
Additional files
Additional file 1: Figure S1. Instability of missense mutant VHL
proteins was caused by UCP. (A) Schematic diagram of missense
mutation of VHL used in this study. (B) Seven recombinant protein of
pVHL missense mutants were ubuiquitinated by UCP in vitro.
Ubiquitinated forms were detected by western blot with Flag antibody.
GST tagged recombinant proteins of mutant pVHLs were ubiquitinated
by UCP in vitro. Indicated GST-pVHL and/or His-UCP protein were
incubated at 37°C in the presence of E1 and Flag-ubiquitin. GST-pVHL
polyubiquitination was detected by western blot with Flag antibody.
(TIFF 322 kb)
Additional file 2: Figure S2. Missense mutant pVHL constitute E3
ubiquitin complex in cell. (A) HEK293T cells were transfected with
plasmid expressing GST tagged hotspot mutant pVHL and/or Flag
tagged HIF-1α protein and then detected the interaction using GST-pull
down assay. (B) HEK293T cells were transfected with plasmid expressing
HA tagged mutant pVHL and/or GST tagged Elongin C protein and then
detected the interaction using GST-pull down assay. Interacted mutants
VHL proteins were detected by immunoblot as indicated. (TIFF 201 kb)
Additional file 3: Figure S3. Ubiquitination is decreased in lysine zero
mutant pVHL in cells significantly. (C) Single-lysine (K159, K171, and K196)
and lysine-zero mutant pVHLs were analyzed in vitro ubiquitination assay.
GST-tagged VHL was incubated with E1, Flag-ubiquitin and His-UCP at 37
°C for 1 h. Each GST-VHL was pulled-down with glutathione sepharose
beads and analyzed by anti-GST or anti-HA antibody. (TIFF 115 kb)
Additional file 4: Figure S4. RCC related missense mutant pVHL
regulate HIF-2α target gene in mRNA level. (A) Conventional RT-PCR for
HIF-2α target genes. Missense mutant VHL expressing 786-O stable cell
line at 48 h after seeding and it was used for quantitation of transcripts
of Glut-1, VEGF and Epo. (B) Calculation of intensity of band of Fig (A).
(TIFF 190 kb)
Additional file 5: Table S1. Primer sequences for RT-PCR and qRT-PCR.
(TIFF 67 kb)
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